Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Femasys Inc. - Common Stock
(NQ:
FEMY
)
0.5752
-0.0248 (-4.13%)
Streaming Delayed Price
Updated: 3:06 PM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Femasys Inc. - Common Stock
< Previous
1
2
3
4
Next >
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
January 14, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
January 13, 2026
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
December 18, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Third Quarter Financial Results for 2025
November 14, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
November 10, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
November 03, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
October 22, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
October 16, 2025
Will Showcase Latest Fertility Solutions
From
Femasys Inc.
Via
GlobeNewswire
Roadzen Inc. (NASDAQ: RDZN) Completes $7M India Financing at 100% Premium – Paves Path to Higher Valuation | More Stocks Inside
October 06, 2025
Via
AB Newswire
Topics
Artificial Intelligence
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
September 25, 2025
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
September 22, 2025
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination
From
Femasys Inc.
Via
GlobeNewswire
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
September 11, 2025
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
September 08, 2025
Expands international footprint with entry into Asia-Pacific, building on recent CE Mark and UK approvals
From
Femasys Inc.
Via
GlobeNewswire
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
September 02, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
August 25, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
August 21, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
August 20, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Second Quarter Financial Results for 2025
August 08, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
August 06, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
July 01, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
June 25, 2025
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women--
From
Femasys Inc.
Via
GlobeNewswire
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
June 17, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
June 11, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
May 30, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
May 29, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
May 08, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
March 27, 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
March 19, 2025
Femasys continues to expand access and market share for its first-line infertility treatment option
From
Femasys Inc.
Via
GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
March 18, 2025
Via
ACCESS Newswire
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
March 18, 2025
From
Femasys Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
